This is such a big thing. Results of a study just published. Semaglutide is a DIABETES medication in origin. But it's effects are so beneficial that now it can be a WEIGHT management medication in the overweight or obese patient profile with prior cardiovascular disease (even if you don't have diabetes). Proven to reduce the combination end point of cardiovascular deaths, non fatal heart attacks and strokes. #cardiology #weightloss #lifestyle
SELECT trial results presented at #AHA23 show in adults with overweight or obesity who do not have diabetes, semaglutide reduced the risk of major adverse cardiovascular events by 20%.
Wow this is awesome
Interventional Cardiologist @ National Heart Institute, IJN 🇲🇾 MBBS(Manipal), MRCP(London), AM(MAL), FRCP (Edinburgh), FAPSIC (Asia-Pacific), EAPCI(EU), HFA(ESC), EECC(EU)
9moPhenomenal results. Proud to be a part of this trial in my centre 👍🏽😊